Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 8/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.44 |
| ▸ | HPGDS | O60760 | 2/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7464202 | 0.94 | USP30 (0.54) | USP30PIK3CDHPGDSGPR119PIK3CA | |
| SCHEMBL7465754 | 0.90 | PIK3CD (0.48) | USP30PIK3CDGPR119PIK3CAPIK3CB | |
| SCHEMBL14778459 | 0.90 | PIK3CD (0.48) | USP30PIK3CDGPR119PIK3CAPIK3CB | |
| SCHEMBL7463050 | 0.90 | PIK3CD (0.48) | USP30PIK3CDGPR119PIK3CAPIK3CB | |
| SCHEMBL7466419 | 0.87 | GPR119 (0.54) | USP30PIK3CDGPR119PIK3CAPIK3CB | |
| SCHEMBL18318139 | 0.84 | GPR119 (0.53) | GPR119 | |
| SCHEMBL14780123 | 0.84 | CHEK2 (0.49) | USP30PIK3CD | |
| SCHEMBL14780124 | 0.84 | CHEK2 (0.49) | USP30PIK3CD | |
| SCHEMBL16195910 | 0.84 | CHEK2 (0.49) | USP30PIK3CD | |
| SCHEMBL4264039 | 0.84 | GPR119 (0.51) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | LIN NAN-HORNG (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1212319-A2 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | Abbott Laboratories (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001019817-A2 | 3-PYRROLIDINYLOXY-3'-PYRIDYL ETHER COMPOUNDS USEFUL FOR CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION | ABBOTT LABORATORIES (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151712-A1 | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission | GAP43, SLC18A2, GABRE | USP30 2742/4885PIK3CD 1341/4885HPGDS 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.